Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer
Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non–small cell lung cancer.
Sukhmani Padda, MD, an assistant professor of medicine at Stanford Cancer Institute, discusses the role of immunotherapy in patients withEGFR-positive nonsmall cell lung cancer (NSCLC).
Immunotherapy has not been the biggest hit yet for this patient population, says Padda. However, it can play a role in a more selective patient population.
Immunotherapy should only be considered for these patients withEGFR-mutant NSCLC after all targeted therapies have been tried, as well as a platinum doublet chemotherapy. However, even in patients with high PD-L1 expression, the response rates with immunotherapy have not been that high.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
